TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00433394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cancer prevention intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cancer prevention intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: educational intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: educational intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: educational intervention
Study: NCT03241862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Silk
Description: Restylane® Silk (Galderma Laboratories, L.P.) is a hyaluronic acid injectable filler, which is approved by the FDA for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids.
Study: NCT04090671

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Multidimensional Dyspnea Profile
Description: The Multidimensional Dyspnea Profile measures the intensity of dyspneic breathing discomforts. It tests five sensory qualities that describe the patient's dyspnea in its respective intensity. Additionally it includes five potential reactions. The MDP is designed to refer to a specific event of time.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Multidimensional Dyspnea Profile
Description: The Multidimensional Dyspnea Profile measures the intensity of dyspneic breathing discomforts. It tests five sensory qualities that describe the patient's dyspnea in its respective intensity. Additionally it includes five potential reactions. The MDP is designed to refer to a specific event of time.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Multidimensional Dyspnea Profile
Description: The Multidimensional Dyspnea Profile measures the intensity of dyspneic breathing discomforts. It tests five sensory qualities that describe the patient's dyspnea in its respective intensity. Additionally it includes five potential reactions. The MDP is designed to refer to a specific event of time.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Multidimensional Dyspnea Profile
Description: The Multidimensional Dyspnea Profile measures the intensity of dyspneic breathing discomforts. It tests five sensory qualities that describe the patient's dyspnea in its respective intensity. Additionally it includes five potential reactions. The MDP is designed to refer to a specific event of time.
Study: NCT02019316

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioSteel Sports Drink
Description: Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
Study: NCT04160819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs.
Study: NCT02019316

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isoenergetic Control
Description: Participants will ingest 500ml of Gatorade 3 times during an exercise session.
Study: NCT00302328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: macular hole operation
Description: macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling
Study: NCT03322865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Induction:~Cycle 1 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1,8,15\*~\*In the case of suspected increased risk of severe IRR, the dose of obinutuzumab may be 100 mg intravenously on day 1 in cycle 1, 900 mg on day 2.~Cycle 2-6 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 Maintenance~Start 8 weeks after the last induction cycle for patients at least achieving a partial response after induction:~Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 every 8 weeks for a maximum of 12 infusions unless progression or study drug - related intolerable toxicity
Study: NCT02125526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-aortic balloon pump
Description: The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
Study: NCT00302328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: macular hole operation
Description: macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling
Study: NCT03315000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol and Fluticasone Furoate
Description: Same as vilanterol arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate
Description: Same as fluticasone arm description
Study: NCT03208335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin
Description: The cycles of rh-endostatin's treatment depends on the effect of reaction and tolerance.
Study: NCT02903940

Intervention type: DEVICE
Intervention: CRT+NAVH
Description: Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
Study: NCT04351919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400mg per day during 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg per day during 5 days
Study: NCT04143698

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic retrograde cholangiopancreatography
Description: The duodenoscope will be passed to the duodenum in the standard fashion. Once the papilla has been identified in the duodenum, cannulation of the desired duct will be performed in the standard fashion, with the type of accessories used left to the discretion of the individual endoscopist performing the procedure. If cannulation is considered difficult, advanced cannulation techniques can be used per standard of care at the discretion of the individual endoscopist. The types of accessories used will be left to the discretion of the individual endoscopist and will be dependent on procedure indication and personal preference. Cross-over to the alternate duodenoscope type can be performed at any time if the desired technical maneuver cannot be performed with the designated duodenoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic retrograde cholangiopancreatography
Description: The duodenoscope will be passed to the duodenum in the standard fashion. Once the papilla has been identified in the duodenum, cannulation of the desired duct will be performed in the standard fashion, with the type of accessories used left to the discretion of the individual endoscopist performing the procedure. If cannulation is considered difficult, advanced cannulation techniques can be used per standard of care at the discretion of the individual endoscopist. The types of accessories used will be left to the discretion of the individual endoscopist and will be dependent on procedure indication and personal preference. Cross-over to the alternate duodenoscope type can be performed at any time if the desired technical maneuver cannot be performed with the designated duodenoscope.
Study: NCT04558801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application-based lifestyle change program
Description: Usage of the Mobile application-based lifestyle change program

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile application-based lifestyle change program
Description: Usage of the Mobile application-based lifestyle change program
Study: NCT03747133

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Stereotactic Ablative Radiotherapy to renal tumors with a dose of 27.5-40 Gy in 5 fractions.
Study: NCT03208166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doctormate
Description: Ischemic conditioning device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Standard medical care

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Standard medical care
Study: NCT03315000

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Same as placebo arm description
Study: NCT03332862

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: catheter ablation for atrial fibrillation treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: catheter ablation for atrial fibrillation treatment
Study: NCT03456908

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 18F-TFB-PET
Description: Infusion of F-18 TFB and PET / CT imaging

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 18F-TFB-PET
Description: Infusion of F-18 TFB and PET / CT imaging
Study: NCT03353935

Intervention type: OTHER
Intervention: Validated questionnaires
Description: Patients were administered pre- and post-operatively the three validated questionnaires ((FSFI, ICIQ-UI short form Italian, NBD score) investigating sexual, urinary, and fecal function, respectively.
Study: NCT00493688

Intervention type: OTHER
Intervention: Cardiopulmonary Exercise Testing (CPET)
Description: Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
Study: NCT03150173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Onsite treatment
Description: Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced referral
Description: Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: all participants will receive buprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: all participants will receive buprenorphine
Study: NCT04458610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study: NCT02899676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simple arithmetic operations
Study: NCT03841357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection
Description: Supplied as a weekly injection via a pre-filled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection
Description: Supplied as a weekly injection via a pre-filled syringe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs
Study: NCT01484730

Intervention type: DEVICE
Intervention: Multi-Spectral and Laser Speckle Imaging
Description: Changes in skin tissue and blood flow.
Study: NCT02388386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROTEUS-SENSOR
Description: An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
Study: NCT02899676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simple arithmetic operations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simple arithmetic operations
Study: NCT04349124

Intervention type: DRUG
Group type: OTHER
Intervention: Nifedipine Extended-Release Tablets
Description: Antihypertensive
Study: NCT01007851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin acetate
Description: single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl %0.9
Description: 0.1 ml sterile saline sc injection 3 days after embryo transfer
Study: NCT00432445

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmic EUA
Description: Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
Study: NCT02241642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIVASURE CLOSURE DEVICE™
Description: Large hole vascular closure device
Study: NCT00005908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel - Dose A
Description: Dose A-Cohort 1 Docetaxel 75 mg/m\^2 intravenous day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg orally daily for five years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg orally daily for five years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m\^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m\^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel - Dose B
Description: Dose B - Cohort 2 Docetaxel 60 mg/m\^2 intravenous day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: 60 mg/m\^2 will be administered as a slow intravenous push on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: 60 mg/m\^2 will be administered as a slow intravenous push on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: 20 mg/day orally for five years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: 20 mg/day orally for five years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine - Dose B
Description: Dose B - Cohort 2 capecitabine 937.5 mg/m\^2 orally twice daily day 2-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine - Dose A
Description: capecitabine 1000 mg/m\^2 orally twice daily day 2-15 for 4 cycles
Study: NCT00475436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Study: NCT03003923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taste exposure
Description: Exposure to the same vegetable

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taste exposure
Description: Exposure to the same vegetable

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: Eat Well and Strive for Five nutritional education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: Eat Well and Strive for Five nutritional education
Study: NCT02831439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic public reporting
Description: The basic intervention will comprise public reporting through the WCHQ website. Individual-level, claims data submitted for billing to third party payers by participating healthsystems will be used to (i) identify cohorts of women with incident breast cancer at the practice-level and (ii) construct the metrics for public reporting and individual benchmarking information. These data are consistent with Medicare and Marketscan claims in both format and content thereby ensuring seamless application of the validated algorithm as well as construction of outcome variables as proposed in Aims 1 and 2 of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Description: The enhanced intervention adds an app comprising a decision tool, patient education and communication information that will be delivering concise, readily accessible information about the main components of the intervention. Specifically, physicians in participating practices will be provided a smartphone-based, point-of-care application that will include i) a list of the unproven/ineffective interventions with statements about a) scientifically proven appropriate use; b) proven or suspected downsides to inappropriate use; ii) clinical calculators that allow physician to input individual patients' clinical/tumor characteristics for each test; iii) practice-specific summary of publicly reported results; and iv) printable patient information adapted from the ASCO Choosing Wisely website.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group - observational
Description: Comparison states will be used to evaluate the interventions in light of possible secular trends in the region and the nation. The design strategy will enable estimates of the effectiveness of the basic intervention (Aim 1) by comparing (i) the pre-intervention rates to post-intervention rates as well as by comparing (ii) changes between the pre- and post-intervention periods for the treatment state (WI) relative to comparison states, neighboring states and others. A similar approach will be used in Part II to provide estimates of the enhanced intervention's impact relative to the basic intervention and contemporary usual care provided in control states, thereby enabling the cost-savings analyses proposed as part of Aim 3.
Study: NCT01264484

Intervention type: DEVICE
Intervention: Advantage Prosthetic Heart Valve
Description: All patients eligible for this study are treated with an Advantage prosthetic heart valve
Study: NCT03268226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
Description: An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg)
Study: NCT03386591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Comparing pharmacokinetics of naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Comparing pharmacokinetics of naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Comparing pharmacokinetics of naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Comparing pharmacokinetics of naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Comparing pharmacokinetics of naloxone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal atomization device and syringe
Description: Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal atomization device and syringe
Description: Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narcan
Description: Nasal Spray

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narcan
Description: Nasal Spray

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramuscular Auto Injector
Description: Intramuscular injection
Study: NCT00501410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400 mg/m\^2 by vein over 46 Hours On Days 1 \& 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Initial Dose = 400 mg/m\^2 by vein, then 250 mg/m\^2 Weekly On Days 1 \& 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose level: 100 mg by mouth daily on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2 by vein on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2 by vein on day 1.
Study: NCT01031511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: 16 weekly sessions of 1.5 hrs in small groups of 3-4 children conducted by 2 therapists

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Social Recreational
Description: 16 weekly sessions of 1.5 hrs in small groups of 3-4 children, conducted by 2 therapists
Study: NCT04167319

Intervention type: OTHER
Intervention: QST and PRO measurements during treatment
Description: We will observe the natural course of CIPN using multiple measurements

Intervention type: OTHER
Intervention: QST and PRO measurements during treatment
Description: We will observe the natural course of CIPN using multiple measurements
Study: NCT01220466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STAR S4IR LASIK with iDesign Aberrometer
Description: CustomVue LASIK targeted for emmetropia
Study: NCT00912743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 400 mg po bid continuously
Study: NCT00003611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acitretin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03563131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona® total knee arthroplasty
Description: Insertion of the cemented or uncemented Persona® total knee arthroplasty
Study: NCT01195012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helping HAND (Healthy Nutrition and Activity Directions)
Description: 6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
Study: NCT03259464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: 3 sequential dose groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 sequential dose groups